A platform that goals to alter outcomes for canine identified with most cancers just lately obtained $10 million in new funding that can permit the corporate to develop and provides extra canine entry to precision therapy.
FidoCure makes use of genetic testing to establish what genetic mutation could be behind a canine’s most cancers. Once testing is full, FidoCure gives precision medication studies with suggestions for individualized, focused remedy utilizing the most recent science out there in each human and canine oncology. FidoCure is on the market nationwide by way of greater than 200 taking part veterinarians.
To study extra, go to fidocure.com.